Update: Reports of suicidality in patients taking diabetes/obesity medicines

Abstract

The below is from a January 11 Drug Safety Communication from the U.S. Food and Drug Administration (FDA) evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs). The initial evaluation found that there is no evidence of a link between these medicines and suicidality. Below is the FDA's report.